Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 23, 2024Open Access

Unraveling New Therapeutic Targets in Ankylosing Spondylitis: Multi-Omics Mendelian Randomization on Immune Cells, Metabolites, and Inflammation Proteins

View Full Paper
Ask AI
Bookmark
Share

Authors

KDKai DuALAo LiCZChen‐Yu Zhang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Du et al. (2024) studied this question.

synapsesocial.com/papers/68e6e092b6db64358765bd98https://doi.org/10.21203/rs.3.rs-4231924/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proteome-Wide Mendelian Randomization in Ankylosing Spondylitis2026
  2. 2Causal relationship between the immune cells and ankylosing spondylitis: univariable, bidirectional, and multivariable Mendelian randomization2024 · 5 citations
  3. 3Association between 1400 blood metabolites and the risk of ankylosing spondylitis: A 2-stage, 2-sample Mendelian randomization study2026
  4. 4The Application, Advantages, and Limitations of Mendelian Randomization Analysis in Ankylosing Spondylitis2026
  5. 5Mendelian randomization analysis links HLA-DR+ CD14- CD16+ monocytes to CCL19-driven ankylosing spondylitis risk.2026